People with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod experienced better relapse control versus those treated with teriflunomide, but disability progression was similar in the two treatment groups.
Why this matters
In the absence of head-to-head trials comparing oral drugs for treatment of MS, real-world comparative data can help physicians and patients make informed, individualized treatment decisions.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.